ArticleJournal of clinical microbiology2013
Taxonomy and antifungal susceptibility of clinically important Rasamsonia species.
Article in Journal of clinical microbiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Manogepix demonstrates potentAntimicrobial agents and chemotherapy · 2026Article
- SystemicMedical mycology case reports · 2026Article
- Comparative volatilomics identifies ubiquitous sulfur compounds inhibiting the fungal pathogenMicrobiology spectrum · 2026Article
- Article
- First case of invasiveMedical mycology case reports · 2024Article
- Emerging Microorganisms and Infectious Diseases: One Health Approach for Health Shared Vision.Genes · 2024Review
- DisseminatedMedical mycology case reports · 2024Article
- Comprehensive antifungal investigation of natural plant extracts against Neosartorya spp. (Aspergillus spp.) of agriculturally significant microbiological contaminants and shaping their metabolic profile.Scientific reports · 2024Article
- Two new species of Trichocomaceae (Eurotiales), accommodated in Rasamsonia and Talaromyces section Bacillispori, from the Czech Republic.Scientific reports · 2023Article
- Non-Journal of fungi (Basel, Switzerland) · 2023Review
- Diagnosis from Tissue: Histology and Identification.Journal of fungi (Basel, Switzerland) · 2022Article
- Emerging Fungal Infections: New Species, New Names, and Antifungal Resistance.Clinical chemistry · 2021Review
- Antifungal Susceptibility Testing: A Primer for Clinicians.Open forum infectious diseases · 2021Review
- Disseminated Rasamsonia argillacea species complex infections in 8 dogs.Journal of veterinary internal medicine · 2021Article
- Classification ofStudies in mycology · 2020Article
- Fungal Diversity of Deteriorated Sparkling Wine and Cork Stoppers in Catalonia, Spain.Microorganisms · 2019Article
- Article
- From the Clinical Mycology Laboratory: New Species and Changes in Fungal Taxonomy and Nomenclature.Journal of fungi (Basel, Switzerland) · 2018Review
- Prevention of Infectious Complications in Patients With Chronic Granulomatous Disease.Journal of the Pediatric Infectious Diseases Society · 2018Review
- Fungus-Specific CD4 T Cells as Specific Sensors for Identification of Pulmonary Fungal Infections.Mycopathologia · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, Geosmithia argillacea has been increasingly reported in humans and animals and can be considered an emerging pathogen. The taxonomy of Geosmithia was recently studied, and Geosmithia argillacea and related species were transferred to the new genus Rasamsonia. The diversity among a set of Rasamsonia argillacea strains, including 28 clinical strains, was studied, and antifungal susceptibility profiles were generated. Data obtained from morphological studies and from phylogenetic analyses of internal transcribed spacer (ITS) and partial β-tubulin and calmodulin sequences revealed the presence of four species in the Rasamsonia argillacea complex, two of which are newly described here: R. piperina sp. nov. and R. aegroticola sp. nov. In contrast to other related genera, all Rasamsonia species can be identified with ITS sequences. A retrospective identification was performed on recently reported clinical isolates from animal or human patients. Susceptibility tests showed that the antifungal susceptibility profiles of the four members of the R. argillacea complex are similar, and caspofungin showed significant activity in vitro, followed by amphotericin B and posaconazole. Voriconazole was the least active of the antifungals tested. The phenotypically similar species R. brevistipitata and R. cylindrospora had different antifungal susceptibility profiles, and this indicates that correct species identification is important to help guide appropriate antifungal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.